This study focuses on people who are waiting for a deceased donor kidney transplant and, as determined at the time of transplant, are receiving a donated kidney at risk of damage from having decreased oxygen levels. Risk factors for damage are thought to include factors that cannot be readily changed, such as donor qualities (age, birth sex, race, medical history), how much time it takes to get the donated kidney to the recipient’s hospital, and perhaps how it was transported (on ice or in a pumped machine). Researchers want to understand how it happens and how to protect against it. This study hopes to determine whether a drug called berinert, when injected into the transplanted kidney right before the operation, can interrupt the damage process and improve kidney function in the first year after transplant. Researchers also want to determine the effects that berinert will have in the kidney recipient. All participants will have a 50% chance of receiving a kidney that has been injected with berinert and a 50% chance of receiving a kidney that has been injected with placebo (inactive substance). The dose of berinert or placebo will be recorded, and participants will be monitored for side effects. Blood, kidney tissue, and urine will be collected for research tests. The use of berinert in this study is considered experimental.